Merck crosses the finish line with its next-gen pneumococcal vaccine. Does it stand a chance against Pfizer's 20-valent shot?
Merck has crossed the FDA finish line with its next-generation pneumococcal vaccine, succeeding in its efforts to one-up — or rather, two-up — Pfizer’s 13-strain shot, Prevnar 13. But can it compete with Pfizer’s recently approved 20-strain shot?
Merck announced a win for V114, to be marketed as Vaxneuvance, in adults 18 years and older on Friday. The shot covers all 13 strains covered by Pfizer’s Prevnar 13 — 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F — plus an additional two, 22F and 33F.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 113,300+ biopharma pros reading Endpoints daily — and it's free.